What can we learn from the DELUGE trial about improving early lung cancer detection? Key takeaways from this important study presented at #ASCO25: ✅ Consider alternative risk criteria ✅ Incorporate broader risk factors beyond smoking New ideas, better screening. #ASCO25 ASCO

☢️ Futility of atezolizumab + SBRT in early stage NSCLC. #ASCO25 #lcsm

#ASCO25 Insightful discussion by Lizza Hendriks on perioperative strategies focusing on: ✔️subgroups of patients in need for escalation: nonPCR, PDL1neg, non-ctDNA clearance, p53(+) for EGFR ✔️ways to improve pCR rates: CRT, ICI combos, ADCs? Ami for EGFR+ #some #LCSM ASCO

Certainly agree with Jordi Remon that DELLI was a very brave study; it appears though that ultra-low dose of IO still provides OS benefit when compared to chemo in ≥ 2L. Masterful presentation as usual. #ASCO25 ASCO #lcsm #lcam

#ASCO25 Developmental Therapeutics CSS🔥 Another presentation on timing of chemo-IO, this time a large observational study of early (<11:30am) v late (>11:30am) IO: - early assoc with benefit in PFS & OS - OS HR 0.49 - pooled cohort of >700pts from 🇨🇳+🇫🇷 ASCO OncoAlert

If I send you this it means things look very bleak but there’s still hope

🔥📣The 2025 #ASCOEdBook collection from ASCO #ASCO25 is now complete & fully available (for free). ✅It’s a great resource with very EDUCATIONAL peer-reviewed articles by great experts. Outstanding job by editors & authors.👏 Link to full edition👇🏻 bit.ly/44bvEkk

Dr. Tony Mok discusses #EGFR at #CIOT25. Emerging combinations like MARIPOSA and FLAURA2 improving outcomes - key is patient selection. Chemo-IO is out based on CM722 and KN789 but HARMONi could change things if OS superior. ADCs in 3L instead of 2L?

#ELIXR25🍁 Thought-provoking talk by Mara Antonoff, MD, FACS on whether staging should be based on biology rather than anatomy- YES! Supporting thoughts: - deferring prognosis evaluation until initial response to Tx - propose local Tx after systemic tx MD Anderson Cancer Center OncoAlert #LCSM

Inflammation in the brain can be beneficial or pathogenic. It varies across neurological diseases. And many new ways are emerging to modulate it An outstanding new review Science Magazine science.org/doi/10.1126/sc…

🌍 How is lung cancer managed around the world? Join us July 3 for a global tumor board tackling real case discussions from diagnosis to survivorship. Featuring experts: Rajat Thawani, Ilit Turgeman, Pramesh CS, Roselle De Guzman, Pablo Munoz Schuffenegger & more! 🔗 bit.ly/43WgnFa

Published nature : Air pollution may drive TP53 and other mutations in lung cancer among never-smokers. EGFR was common in East Asia, KRAS in the West; secondhand smoke showed minimal genomic impact, and herbal toxin–linked signatures were seen in Taiwan.

🔬 Who Should Get Screened for Pancreatic Cancer? Insights from #ESMOGI25 🔎 📌 High-Risk Germline Mutations 🧬 STK11 (Peutz-Jeghers): RR ~132 | Lifetime risk: 11–36% 🧬 PRSS1 (Hereditary Pancreatitis): RR 53–87 | Risk up to 55% by age 70 🧬 CDKN2A (FAMMM): RR 20–40 | Risk 17–25%

💡Starting out in thoracic oncology? The IASLC Communications Committee proudly brings you: ‘50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic’ A whistlestop tour of key advances, distilled by global leaders JTO & JTO CRR OncoAlert #LCSM jto.org/article/S1556-…

Consensus statement from IASLC on molecular tumor boards in lung cancer (& oncology in general). Provides framework for implementation, report standardization, case selection, quality assessment. Performance metric: changes in management based on MTB. jto.org/article/S1556-…

1/11 Our study on subclonal immune evasion in non-small cell lung cancer has just been published in Cancer Cell cell.com/cancer-cell/fu…

Hot off the press a 🚨 Must-read review on optimizing treatment for #LungCancer with activating EGFR mutations , a true game changer in targeted therapy. TKIs have transformed outcomes, but the journey continues. 👉 acsjournals.onlinelibrary.wiley.com/doi/full/10.33… thanks to all the co-authors, great team

FLAURA2 press release: addition of chemotherapy to 1L osimertinib in #EGFR NSCLC improves overall survival. Already approved based on significant PFS benefit. Awaiting data to see degree of OS benefit to consider vs MARIPOSA. Important positive update! astrazeneca.com/media-centre/p…

You need some data as to how to use dato? Below guide offers a practical way to use Datroway in your clinic! ☑️mucositis ☑️pneumonitis ☑️ocular tox Now that Dato-dxd is approved for both breast and EGFR-mutated NSCLC indications, implementation of best practices is key! 👀

Now online in Cancer Discovery: Eradicating Drug Tolerant Persister Cells in EGFR-Mutated NSCLC by Targeting TROP2 with CAR-T Cellular Therapy - by Simon Baldacci, Elliott Brea MD, PhD, Francesco Facchinetti, Eric Smith, Pasi Jänne, David Barbie, and colleagues doi.org/10.1158/2159-8… Dana-Farber